{"date":"2025-02-05","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4172-2025-02-05-1603-zmbytt","company_id":"4172","company":"因華","market":"興櫃","industry":"生技醫療","date":"2025-02-05","time":"16:03:57","subject":"公告本公司新藥D07001軟膠囊劑之晚期膽道癌患者之二三期臨床試驗，其第一階段已完成收案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：因華（4172），2025-02-05 16:03，「公告本公司新藥D07001軟膠囊劑之晚期膽道癌患者之二三期臨床試驗，其第一階段已完成收案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2025-02-05-1419-5zktdg","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2025-02-05","time":"14:19:35","subject":"公告本公司訂定113年現金增資普通股之認股基準日相關事宜(補充發行價格、代收價款行庫及專戶存儲行庫)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2025-02-05 14:19，「公告本公司訂定113年現金增資普通股之認股基準日相關事宜(補充發行價格、代收價款行庫及專戶存儲行庫)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}